RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Venous thrombosis
- Focus Therapeutic Use
- Acronyms RE-SPECT CVT
- Sponsors Boehringer Ingelheim
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2017 Planned End Date changed from 19 May 2018 to 27 Jun 2018.
- 03 Oct 2017 Planned primary completion date changed from 5 May 2018 to 27 Jun 2018.